4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-017532
CHIEF FINANCIAL OFFICER sold 3,000 shares at $22.55 ($67,655)
- CHIEF FINANCIAL OFFICER acquired 3,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-06-13 | Option exercise 10b5-1 | +3,000 | $2.48 | $7,440 | 26,000 | D: show line 1 in the form |
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-06-13 | Sale 10b5-1 | −3,000 | $22.55 | $67,655 | 23,000 | D: show line 2 in the form |
| Open-market sales · 3,000 sh · avg $22.55 · $67,655 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin CHIEF FINANCIAL OFFICER | 2025-06-13 | Option exercise · Stock Option (right to buy) 10b5-1 | −3,000 | 119,056 | D: show line 3 in the form |
Loading xslF345X05/form4-06172025_080605.xml…